January 1, 1996Blood Pressure
Safety Aspects of Treatment with Lacidipine—A Slow-onset, Long-acting Calcium Antagonist
Why the study?
Does lacidipine safely and effectively lower blood pressure in patients with hypertension?
Population
18,851 hypertensive patients from 50 phase III-IV trials
Comparison
Lacidipine 2-6 mg vs Active comparative treatment or placebo
Design
Review, Double blind for comparative trials, open for others
Follow-up
relatively short period of time (one study was 48 weeks)
Authors
Discussion
Loading...
Member takes
Implication
Lacidipine may lower BP with typical tolerability; leaves open its comparative role versus contemporary agents in prospective trials.
Structured PICO
Does lacidipine safely and effectively lower blood pressure in patients with hypertension?
P
Population
18,851 hypertensive patients (16,590 received lacidipine, 1,810 active comparator, 451 placebo) from 50 phase III-IV trials
I
Intervention
Lacidipine 2-6 mg
C
Comparator
Active comparative treatment (other calcium antagonists, diuretics, beta-receptor blockers, ACE inhibitors) or placebo
O
Outcome
Fatal and non-fatal cardiovascular events, efficacy (change in blood pressure and heart rate), adverse event rates, and drop-out ratessafety
Lacidipine is an effective and well-tolerated calcium antagonist for hypertension with a typical dihydropyridine adverse effect profile.
Limitations
- retrospective analysis of data obtained from a large cohort of patients
- most patients received lacidipine for a relatively short period of time
Cite This Study
Lindholm et al. (1996) studied this question.